366 related articles for article (PubMed ID: 31421906)
1. Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption.
Sprowls SA; Arsiwala TA; Bumgarner JR; Shah N; Lateef SS; Kielkowski BN; Lockman PR
Trends Cancer; 2019 Aug; 5(8):495-505. PubMed ID: 31421906
[TBL] [Abstract][Full Text] [Related]
2. The blood-brain barrier: its influence in the treatment of brain tumors metastases.
Fortin D
Curr Cancer Drug Targets; 2012 Mar; 12(3):247-59. PubMed ID: 22229251
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-mediated disruption of the blood tumor barrier for improved therapeutic delivery.
Arsiwala TA; Sprowls SA; Blethen KE; Adkins CE; Saralkar PA; Fladeland RA; Pentz W; Gabriele A; Kielkowski B; Mehta RI; Wang P; Carpenter JS; Ranjan M; Najib U; Rezai AR; Lockman PR
Neoplasia; 2021 Jul; 23(7):676-691. PubMed ID: 34139452
[TBL] [Abstract][Full Text] [Related]
4. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases.
Arvanitis CD; Ferraro GB; Jain RK
Nat Rev Cancer; 2020 Jan; 20(1):26-41. PubMed ID: 31601988
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
Drapeau A; Fortin D
Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
[TBL] [Abstract][Full Text] [Related]
8. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
[TBL] [Abstract][Full Text] [Related]
10. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier.
Parrish KE; Sarkaria JN; Elmquist WF
Clin Pharmacol Ther; 2015 Apr; 97(4):336-46. PubMed ID: 25669487
[TBL] [Abstract][Full Text] [Related]
11. Targeting microbubbles-carrying TGFβ1 inhibitor combined with ultrasound sonication induce BBB/BTB disruption to enhance nanomedicine treatment for brain tumors.
Chen YC; Chiang CF; Wu SK; Chen LF; Hsieh WY; Lin WL
J Control Release; 2015 Aug; 211():53-62. PubMed ID: 26047759
[TBL] [Abstract][Full Text] [Related]
12. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine.
Kim M; Kizilbash SH; Laramy JK; Gampa G; Parrish KE; Sarkaria JN; Elmquist WF
Pharm Res; 2018 Jul; 35(9):177. PubMed ID: 30003344
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
14. Unsanctifying the sanctuary: challenges and opportunities with brain metastases.
Puhalla S; Elmquist W; Freyer D; Kleinberg L; Adkins C; Lockman P; McGregor J; Muldoon L; Nesbit G; Peereboom D; Smith Q; Walker S; Neuwelt E
Neuro Oncol; 2015 May; 17(5):639-51. PubMed ID: 25846288
[TBL] [Abstract][Full Text] [Related]
15. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
Doolittle ND; Peereboom DM; Christoforidis GA; Hall WA; Palmieri D; Brock PR; Campbell KC; Dickey DT; Muldoon LL; O'Neill BP; Peterson DR; Pollock B; Soussain C; Smith Q; Tyson RM; Neuwelt EA
J Neurooncol; 2007 Jan; 81(1):81-91. PubMed ID: 16858513
[TBL] [Abstract][Full Text] [Related]
16. Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor.
Black KL; Ningaraj NS
Cancer Control; 2004; 11(3):165-73. PubMed ID: 15153840
[TBL] [Abstract][Full Text] [Related]
17. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.
D'Amico RS; Khatri D; Reichman N; Patel NV; Wong T; Fralin SR; Li M; Ellis JA; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2020 Apr; 147(2):261-278. PubMed ID: 32076934
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.
Baumann BC; Kao GD; Mahmud A; Harada T; Swift J; Chapman C; Xu X; Discher DE; Dorsey JF
Oncotarget; 2013 Jan; 4(1):64-79. PubMed ID: 23296073
[TBL] [Abstract][Full Text] [Related]
19. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
